Step 1: Identify the drug. The image shows vials of Mitomycin C (10 mg and 40 mg). Mitomycin C is an antineoplastic antibiotic derived from Streptomyces caespitosus that inhibits DNA synthesis by cross-linking DNA strands. It also inhibits fibroblast proliferation and collagen synthesis.
Step 2: Mechanism of topical Mitomycin C in ENT. When applied topically, Mitomycin C inhibits fibroblast proliferation, thereby preventing scar formation and stenosis. This anti-fibrotic property makes it useful to prevent or treat narrowing (stenosis) after surgical procedures on the airway.
Step 3: ENT applications of topical Mitomycin C. Topical Mitomycin C is used in:
- Subglottic stenosis (to prevent re-stenosis after endoscopic dilation or surgery)
- Tracheal stenosis after tracheostomy
- Laryngeal stenosis
- FESS (functional endoscopic sinus surgery) to prevent ostial stenosis
- Septoplasty (to prevent synechiae formation)
- Intubation granuloma treatment
Step 4: Eliminate distractors. Myringoplasty uses grafts (temporalis fascia, perichondrium) -- not Mitomycin C. Post-adenoidectomy bleeding is managed by cautery, packing, or re-ligation -- not Mitomycin C. Rhino-cerebral mucormycosis is treated with antifungals (amphotericin B) and surgical debridement -- not Mitomycin C.
Conclusion: The topical ENT use of Mitomycin C is in subglottic stenosis.